Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

CDK4/6 inhibitors show promise but their efficacy varies, highlighting the need for biomarkers. This study explores TRIM4's role in ovarian cancer's response to CDK4/6 inhibitors, revealing that ...

7 Residual cancer cells present beyond these times are likely to be resistant to treatment. Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability ...

The study, which included data from 6 institutions in Italy and more than 500 patients, was described by Dr. Criscitiello as “one of the largest analyses in the post-CDK4/6i setting.” ...

CDK4/6 inhibitor Verzenio (abemaciclib) was the third drug in the class to reach the market, first approved in 2017 as a second-line treatment for post-menopausal patients with hormone receptor ...

Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial The following ...